2005
Suchergebnisse
Suchergebnisse:
Vor 13 Stunden · FOSTER CITY, Calif.--(BUSINESS WIRE)--May 31, 2024--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that the European Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion of LIVMARLI® (maralixibat) oral solution for the treatment of Progressive Familial Intrahepatic Cholestasis (PFIC) in patients three months of age and older.